| scholarly article | Q13442814 |
| P50 | author | Paul J Thornalley | Q56810389 |
| P2093 | author name string | Michèle Geoffrion | |
| Naila Rabbani | |||
| Vivette D D'Agati | |||
| Michael Brownlee | |||
| Barbara C Vanderhyden | |||
| Guangzhi Sui | |||
| Kerri Courville | |||
| Ross W Milne | |||
| Sylvie Ott-Braschi | |||
| Xueliang Du | |||
| Zehra Irshad | |||
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes | Q24608214 | ||
| Insulin resistance, hyperglycemia, and atherosclerosis | Q27011696 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation | Q28187673 | ||
| Therapeutic potential of breakers of advanced glycation end product–protein crosslinks | Q28211259 | ||
| Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy | Q28266524 | ||
| In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites | Q28305676 | ||
| Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation | Q28473799 | ||
| High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A | Q28593917 | ||
| Differential accumulation of advanced glycation end products in the course of diabetic retinopathy | Q30724348 | ||
| Glyoxalase-1 overexpression in bone marrow cells reverses defective neovascularization in STZ-induced diabetic mice. | Q31144176 | ||
| Protein glycation, diabetes, and aging | Q32120059 | ||
| Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands | Q33556567 | ||
| Hyperglycemia impairs proteasome function by methylglyoxal | Q33688582 | ||
| Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis | Q33714947 | ||
| Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress | Q33773237 | ||
| Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse | Q34024334 | ||
| Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes | Q34108497 | ||
| Advanced glycation end-products: a review | Q34196489 | ||
| Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond | Q34282992 | ||
| The glyoxalase system in health and disease | Q34347556 | ||
| Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function | Q34355343 | ||
| Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats | Q34489018 | ||
| Diabetes and advanced glycation endproducts | Q34521835 | ||
| Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress | Q34534524 | ||
| Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. | Q44325186 | ||
| The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. | Q44575244 | ||
| Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. | Q44953934 | ||
| Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. | Q45000524 | ||
| Serum lipids and glucose control: the SEARCH for Diabetes in Youth study | Q46255460 | ||
| Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. | Q46713789 | ||
| Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy | Q46881248 | ||
| RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin | Q47323805 | ||
| Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. | Q47785594 | ||
| Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products | Q47876980 | ||
| Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. | Q53786578 | ||
| Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. | Q54397160 | ||
| Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group | Q68032851 | ||
| Glyoxalase I from mouse liver | Q70548265 | ||
| The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions | Q71070390 | ||
| Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation | Q72068618 | ||
| Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial | Q72198055 | ||
| Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats | Q72324013 | ||
| Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct | Q74110788 | ||
| Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase | Q77752908 | ||
| Quantification of atherosclerosis in mice | Q78308913 | ||
| Intervention against the Maillard reaction in vivo | Q79185026 | ||
| Increased urinary TGF-beta1 and cortical renal GLUT1 and GLUT2 levels: additive effects of hypertension and diabetes | Q81691489 | ||
| Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology | Q82814955 | ||
| Advanced glycation end products: sparking the development of diabetic vascular injury | Q34555042 | ||
| Advanced glycation endproducts: what is their relevance to diabetic complications? | Q34613062 | ||
| Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy | Q35404877 | ||
| Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter | Q35554090 | ||
| Role of lipids in chemical modification of proteins and development of complications in diabetes | Q35594328 | ||
| Glyoxalase I retards renal senescence | Q35679515 | ||
| Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models? | Q36416215 | ||
| Breakers of advanced glycation end products restore large artery properties in experimental diabetes. | Q36477705 | ||
| Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? | Q36775094 | ||
| Recipes for creating animal models of diabetic cardiovascular disease | Q36831539 | ||
| Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes | Q36842628 | ||
| Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia | Q36916418 | ||
| Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts | Q36939944 | ||
| The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion | Q36939948 | ||
| Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complicat | Q37054987 | ||
| Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study | Q37105165 | ||
| The role of AGEs in cardiovascular disease | Q37160911 | ||
| The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues | Q37304128 | ||
| Diabetes and atherosclerosis: is there a role for hyperglycemia? | Q37333371 | ||
| The pathologic continuum of diabetic vascular disease | Q37380374 | ||
| Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase | Q37388154 | ||
| Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice | Q37403354 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Glycotoxines, carbonyl stress and relevance to diabetes and its complications. | Q37523923 | ||
| Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. | Q37751655 | ||
| Where does plasma methylglyoxal originate from? | Q38064587 | ||
| Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice | Q39781855 | ||
| Methylglyoxal-induced mitochondrial dysfunction in vascular smooth muscle cells | Q39854280 | ||
| Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease | Q39960465 | ||
| Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress | Q40047034 | ||
| Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification | Q40262411 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry | Q42048767 | ||
| Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modi | Q42157625 | ||
| Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells | Q42518796 | ||
| Skin autofluorescence is a strong predictor of cardiac mortality in diabetes | Q43813083 | ||
| Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes | Q43816011 | ||
| Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations | Q43933620 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| overexpression | Q61643320 | ||
| P577 | publication date | 2014-06-11 | |
| P1433 | published in | Physiological Reports | Q15716763 |
| P1476 | title | Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice | |
| P478 | volume | 2 |
| Q42074821 | A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice |
| Q92438095 | Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1 |
| Q38831558 | Cellular mechanisms and consequences of glycation in atherosclerosis and obesity |
| Q34393408 | Dicarbonyl stress and atherosclerosis: is it all RAGE? |
| Q37156152 | Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics |
| Q55104216 | Eucommia ulmoides Ameliorates Glucotoxicity by Suppressing Advanced Glycation End-Products in Diabetic Mice Kidney. |
| Q93105232 | GeneFishing to reconstruct context specific portraits of biological processes |
| Q64081880 | Ginkgo Biloba Leaf Extract Attenuates Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-/- Mice by Inhibiting Endoplasmic Reticulum Stress via Restoration of Autophagy through the mTOR Signaling Pathway |
| Q54114911 | Ginkgo biloba Leaf Extract Protects against Myocardial Injury via Attenuation of Endoplasmic Reticulum Stress in Streptozotocin-Induced Diabetic ApoE-/- Mice. |
| Q47702166 | Glyoxalases in Urological Malignancies |
| Q37631669 | Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage. |
| Q36930808 | Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy |
| Q47725988 | Methylglyoxal-derived advanced glycation end products contribute to negative cardiac remodeling and dysfunction post-myocardial infarction |
| Q38394355 | The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases |
| Q35881759 | Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture |
Search more.